Latest news and insights on the pharmaceutical industry | Indian Pharma Post

Results For "Pharmaceutical"

3535 News Found

Iberia Pharmaceuticals scores big with KeyCi launch, signals shift towards science-backed skincare
News | March 21, 2026

Iberia Pharmaceuticals scores big with KeyCi launch, signals shift towards science-backed skincare

KeyCi’s dermatologically tested lineup emphasizes clean formulations—vegan, cruelty-free, alcohol-free, and paraben-free—while being backed by pharmaceutical-grade research and FDA approval


Rhythm Pharmaceuticals’ Phase 3 EMANATE trial falls short of primary goals
Clinical Trials | March 20, 2026

Rhythm Pharmaceuticals’ Phase 3 EMANATE trial falls short of primary goals

The study included four independent genetic substudies targeting obesity caused by heterozygous variants in the POMC/PCSK1, LEPR, SRC1 (NCOA1), and SH2B1 genes


Glenmark Pharmaceuticals USA launches authorized generic of Savella tablets
News | March 20, 2026

Glenmark Pharmaceuticals USA launches authorized generic of Savella tablets

Glenmark's Milnacipran Hydrochloride Tablets, 12.5 mg, 25 mg, 50 mg, and 100 mg is the authorized generic to Savella Tablets, 12.5 mg, 25 mg, 50 mg, and 100 mg


Clariant boosts US pharmaceutical production with Clear Lake expansion
News | March 20, 2026

Clariant boosts US pharmaceutical production with Clear Lake expansion

The Clear Lake facility marks Clariant’s first U.S. site dedicated to PEG excipient production


Cadila Pharmaceuticals marks 75-year journey of global healthcare innovation
News | March 16, 2026

Cadila Pharmaceuticals marks 75-year journey of global healthcare innovation

Cadila Pharmaceuticals’ journey has been marked by several milestones, including the development of indigenous formulations, expansion into global markets, and the creation of robust manufacturing and R&D capabilities


Glenmark Pharmaceuticals USA to launch Potassium Phosphates Injection USP in multiple vial sizes
News | March 16, 2026

Glenmark Pharmaceuticals USA to launch Potassium Phosphates Injection USP in multiple vial sizes

The product is bioequivalent and therapeutically equivalent to Fresenius Kabi’s reference drug (NDA 212832)


Vertex Pharmaceuticals’ new kidney drug shows dramatic results in Phase 3 trial
Clinical Trials | March 12, 2026

Vertex Pharmaceuticals’ new kidney drug shows dramatic results in Phase 3 trial

The trial met its primary endpoint, with patients receiving povetacicept achieving a 52.0% reduction in UPCR at Week 36


Glenmark Pharmaceuticals USA to launch sodium phosphates injection
News | February 28, 2026

Glenmark Pharmaceuticals USA to launch sodium phosphates injection

The product addresses a market with approximately $66.8 million in annual sales as of December 2025.


Asahi Kasei to acquire German biopharmaceutical company Aicuris for €780 million
News | February 26, 2026

Asahi Kasei to acquire German biopharmaceutical company Aicuris for €780 million

Asahi Kasei is consistently pursuing its strategy of building a focused, sustainable specialty pharmaceutical platform for immunocompromised and medically complex patient groups